&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-11-07, 21:00

Philips program developing AI-powered ultrasound to expand access to maternal health receives major funding boost

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-10-26, 07:57

New Research from Getty Images Shows that Visual Representation of Asian Communities in APAC Advertising Remains Stereotypical

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-10-17, 03:15

Notified Continues 2023 Momentum, Recognized for Groundbreaking AI-Powered Solution for Communicators

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-10-16, 13:00

Copenhagen Infrastructure Partners reaches final close of EUR ~2 billion for two new funds

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-10-03, 21:42

HYPR Expands on Authentication Leadership With First Identity Assurance Solution Addressing Major Identity Security Gaps

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-10-03, 21:00

U.S. Defense Department Awards Eavor Contract to Power Military Base through Advanced Geothermal System

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-09-26, 14:00

Anaqua Builds on its Momentum in Japan with New Leadership, Clients, Solutions and Country HQ

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-09-19, 14:00

Brewing Success: Heineken® Renews Long-Standing Relationship with UEFA Champions League - Marking Over 30 Years Together

[img]http://phpstack-911252-3168991.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=9cf99112-580c-4403-8a13-1bf4bbf88e7b&size=3[/img]

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-09-08, 20:13

The Metals Company Announces Investor Conference Schedule Through End of 2023

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-09-05, 17:00

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Popular Posts